At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SBIO ALPS Medical Breakthroughs ETF
Trading 11-06 13:18:01 EST
55.45
+2.62
+4.96%
High55.45Low53.34Vol12.16K
Open53.34D1 Closing52.83Amplitude4.00%
Mkt Cap185.76MTradable Cap185.76MTotal Shares3.35M
T/O656.88KT/O Rate0.36%Tradable Shares3.35M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Cg Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
Reuters  ·  11-06 21:57
Cg Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
CG Oncology Presents 41.8% Complete Response Rate at 24 Months for Cretostimogene
Reuters  ·  11-06 21:19
CG Oncology Presents 41.8% Complete Response Rate at 24 Months for Cretostimogene
CG Oncology Q3 EPS USD -0.64
THOMSON REUTERS  ·  11-06 21:17
CG Oncology Q3 EPS USD -0.64
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
THOMSON REUTERS  ·  11-06 21:15
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
Genmab Share Price Surge Puts These Oncology Stocks In Focus
Simply Wall St.  ·  11-03
Genmab Share Price Surge Puts These Oncology Stocks In Focus
Xenon Pharmaceuticals Sets Third-Quarter Results Release
Reuters  ·  11-03
Xenon Pharmaceuticals Sets Third-Quarter Results Release
Learn Why The Bull Case For Xenon Pharmaceuticals Stock Could Change Following Pain Trial Progress
Simply Wall St.  ·  11-01
Learn Why The Bull Case For Xenon Pharmaceuticals Stock Could Change Following Pain Trial Progress
Xenon Pharmaceuticals Grants 24,250 Stock Options, 14,250 RSUs to Nine New Employees
Reuters  ·  10-31
Xenon Pharmaceuticals Grants 24,250 Stock Options, 14,250 RSUs to Nine New Employees
Xenon Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  10-31
Xenon Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  10-31
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Reports Positive Phase 1 Results for Pain Drugs Xen1701 and Xen1120
Reuters  ·  10-29
Xenon Reports Positive Phase 1 Results for Pain Drugs Xen1701 and Xen1120
Xenon Announces Positive Phase 1 and New Preclinical Data at Iasp 2026 Supporting Advancement of Xen1701 and Xen1120 to Phase 2 Proof-of-Concept Studies in Acute Pain
THOMSON REUTERS  ·  10-29
Xenon Announces Positive Phase 1 and New Preclinical Data at Iasp 2026 Supporting Advancement of Xen1701 and Xen1120 to Phase 2 Proof-of-Concept Studies in Acute Pain
CG Oncology (CGON) CCO Hire Puts Its Launch Valuation Narrative To The Test
Simply Wall St.  ·  10-22
CG Oncology (CGON) CCO Hire Puts Its Launch Valuation Narrative To The Test
Inside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock Surging
Dow Jones  ·  10-20
Inside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock Surging
CG Oncology Director Leonard E. Post Reports Sale of Common Shares Worth $62,065
Reuters  ·  10-20
CG Oncology Director Leonard E. Post Reports Sale of Common Shares Worth $62,065
CG Oncology Files Initial Beneficial Ownership Statement for Chief Commercial Officer Isabel Kalofonos
Reuters  ·  10-20
CG Oncology Files Initial Beneficial Ownership Statement for Chief Commercial Officer Isabel Kalofonos
Disc Medicine Stock (IRON) Soars Over 28% on a Phase 3 Trial Win
TIPRANKS  ·  10-19
Disc Medicine Stock (IRON) Soars Over 28% on a Phase 3 Trial Win
CG Oncology Names Isabel Kalofonos Chief Commercial Officer
Reuters  ·  10-13
CG Oncology Names Isabel Kalofonos Chief Commercial Officer
CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer
THOMSON REUTERS  ·  10-13
CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer
Xenon Pharmaceuticals Coverage Assumed by Guggenheim at Buy
Dow Jones  ·  10-06
Xenon Pharmaceuticals Coverage Assumed by Guggenheim at Buy

Introduction

Company Name.
ALPS Medical Breakthroughs ETF
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
Issue price:
--